HighGravityDataIncyte — Feb 10, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001628280-25-004514
Showing in the filing
Goal for impactful product launches
“more than 10”
Period
FY2030
Measure
Company-defined measure
Source
Prose
All guidance in this release · 10
Goal for impactful product launches for FY2030
“more than 10”
Jakafi net revenues for FY2025
“$2,925 - $2,975 million”
Opzelura net revenues for FY2025
“$630 - $670 million”
Other oncology net product revenues for FY2025
“$415 - $455 million”
GAAP Cost of product revenues for FY2025
“8.5% - 9.0% of net product revenues”
Non-GAAP Cost of product revenues for FY2025
“7.5% - 8.0% of net product revenues”
GAAP Research and development expenses for FY2025
“$1,930 - $1,960 million”
Non-GAAP Research and development expenses for FY2025
“$1,780 - $1,805 million”
GAAP Selling, general and administrative exp… for FY2025
“$1,280 - $1,310 million”
Non-GAAP Selling, general and administrative… for FY2025
“$1,160 - $1,185 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
"Looking ahead to 2025, we anticipate a year of continued strong revenue growth and diversification, as well as several defining milestones that will serve as an inflection point for Incyte. A year ago, we set the goal to achieve more than 10 impactful product launches by 2030. In 2025, a number of key catalysts across the entire portfolio will bring that goal closer to reality." 2025: A Year of Defining Catalysts Incyte expects to deliver at least 18 key milestones in 2025. These include: • Four new product launches: Niktimvo™ in 3L+ chronic graft-versus-host disease (GVHD), ruxolitinib cream in pediatric atopic dermatitis (AD), tafasitamab in relapsed/refractory follicular lymphoma (FL), and retifanlimab in squamous cell anal carcinoma (SCAC). • At least three Phase 3 study initiations: BET inhibitor in 2L myelofibrosis (MF), ruxolitinib cream in mild to moderate hidradenitis suppurativa (HS) and CDK2 inhibitor in ovarian cancer. • Four pivotal readouts: Povorcitinib in moderate to severe HS, ruxolitinib cream in prurigo nodularis (PN), tafasitamab in 1L diffuse large B-cell lymphoma (DLBCL), and ruxolitinib XR for MF, polycythemia vera (PV), and GVHD. • Seven proof of concept readouts: Povorcitinib in chronic spontaneous urticaria (CSU) and asthma, mutCALR in MF and essential thrombocythemia (ET), JAK2V617F mutant-specific inhibitor in MF, and both KRASG12D and TGFβR2xPD-1 in solid tumors. 1 Key Recent Company Updates • A bioequivalence study
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.